United States-based pharmaceutical and biotechnology corporation Pfizer announced on Thursday that it has named Elif Aral as its new regional president for Middle East, Russia and Africa (MERA), effective September 2024.
In the new role, Aral is to spearhead operations in the region and bring scientific breakthroughs in vaccines, oncology, rare diseases, internal medicine, hospitals and inflammation and immunology. She will also drive strategic initiatives aimed at improving healthcare access and equity, working closely with regional partners and governments to ensure the company's leading portfolio and breakthroughs reach those who need them. This is in addition to managing all therapeutic areas within the MERA region.
Aral began her career with Pfizer in 1995 and most recently led the company's 'An Accord for a Healthier World' initiative. She has served as the CV Metabolic and Global Brands Lead in Internal Medicine and also as the Vaccines Lead for Emerging Markets.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business